Paclitaxin (Paclitaxel)

Paclitaxel is a chemotherapy agent used in several solid‑tumor treatment pathways.

• Breast cancer: improves survival by inhibiting tumor cell proliferation.
• Ovarian cancer: used after surgery to reduce recurrence risk.
• Non‑small cell lung cancer: administered to extend progression‑free survival.
• Kaposi's sarcoma: controls disease spread in immunocompromised patients.
• Gastric cancer: part of combination regimens to shrink tumors.
• Pancreatic cancer: used in advanced disease protocols.

• Paclitaxel binds to β‑tubulin subunits, stabilizing microtubules and preventing their depolymerisation during cell division. This arrest of the mitotic spindle halts the G2/M phase, leading to apoptosis of rapidly dividing cancer cells while sparing most non‑dividing normal tissues.

Paclitaxel may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Neutropenia: reduced white‑blood‑cell count increasing infection risk.
• Alopecia: hair loss affecting scalp and body hair.
• Peripheral neuropathy: tingling or numbness in extremities.
• Nausea and vomiting: gastrointestinal upset.
• Fatigue: generalized tiredness.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: anaphylaxis‑like symptoms.
• Cardiotoxicity: arrhythmias or reduced heart function.
• Severe neutropenic fever: life‑threatening infection.
• Pulmonary toxicity: interstitial pneumonitis.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Secondary malignancies: rare therapy‑related cancers.

When using Paclitaxin, clinicians should observe several safety measures.

• Monitor blood counts: perform regular CBC with differential to detect neutropenia.
• Assess neuropathy: evaluate sensory changes before each dose.
• Pre‑medicate: give antihistamines and corticosteroids to reduce hypersensitivity risk.
• Review cardiac function: baseline ECG and periodic monitoring for arrhythmias.
• Adjust for hepatic impairment: consider dose modification in patients with liver dysfunction.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Paclitaxin may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase paclitaxel exposure.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): reduce paclitaxel levels.
• Concurrent use of other neurotoxic agents (e.g., vincristine): heighten neuropathy risk.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may enhance bleeding tendency.\n- Live vaccines: immunosuppression may diminish vaccine efficacy.
• Strong acid‑reducing agents: potential alteration of absorption when oral formulations are used.